Sanofi’s Enjaymo, the only approved drug therapy for cold agglutinin disease, is being acquired by Recordati for $825 million upfront. The drug targets a rare blood disorder where the immune system attacks red blood cells, causing anemia. Enjaymo interferes with the process of red blood cell destruction by blocking a complement system protein. Approved in the U.S., Japan, and Europe, the drug generated $79 million in sales last year and is projected to reach peak sales of $328 million. Recordati, known for its rare disease portfolio, sees Enjaymo as complementary to its existing products and expects positive financial contributions from the acquisition.
Source link
Health Information Management